Human Studies So Far
Human research on Pueraria mirifica has focused primarily on women during and after menopause. Researchers have investigated several areas, including vasomotor symptoms, vaginal health, reproductive hormone measurements, and markers related to bone turnover.
These studies vary in their design, participants, duration, and measured outcomes. They should be considered individually rather than treated as evidence of one general hormonal effect.
Menopausal symptoms
Several clinical studies have examined Pueraria mirifica in women experiencing menopausal symptoms, including hot flashes and night sweats. A Phase II study evaluated its use in perimenopausal and postmenopausal women and reported changes in climacteric symptom scores during the study period.[1]
Another randomized clinical study compared two tested amounts of Pueraria mirifica in women experiencing menopausal symptoms. Both groups showed lower climacteric scores during the study, with no significant difference between the two groups.[2]
These findings provide preliminary clinical information, but individual studies cannot establish a consistent response for all women.
Vaginal health
Researchers have also investigated vaginal health in postmenopausal women. A randomized, double-blind, placebo-controlled study evaluated vaginal symptoms, vaginal health measurements, vaginal pH, and vaginal cell changes.
The study reported a reduction in vaginal dryness symptoms in the Pueraria mirifica group and changes in the vaginal maturation index after the study period. These findings relate specifically to the participants and measurements in that study.[3]
They should not be interpreted as evidence that all forms or uses of Pueraria mirifica produce the same effects.
Bone and lipid-related measurements
A randomized, double-blind, placebo-controlled study examined lipid profiles and biochemical markers of bone turnover in healthy postmenopausal women.
The researchers reported a decrease in bone-specific alkaline phosphatase in the Pueraria mirifica group compared with placebo. Both groups also showed an increase in triglyceride levels. The study did not establish an improvement in bone density or a general cardiovascular benefit.[4]
These findings are important to distinguish from claims about stronger bones, weight management, or improved cardiovascular health. A change in a biochemical marker does not automatically establish a corresponding long-term health outcome.
What the 2018 Systematic Review Found
A 2018 systematic review by Kongkaew and colleagues assessed clinical trials involving Pueraria mirifica in menopausal and postmenopausal women. The review included eight studies reported in nine articles, involving 309 participants.[5]
The researchers examined several areas:
- Self-reported menopausal symptoms.
- Serum reproductive hormone measurements.
- Urinary and genital tract function.
- Bone-related surrogate measurements.
Five studies reported reductions in climacteric symptom scores compared with baseline. Other studies involving relatively small placebo groups suggested changes in vaginal and other urogenital symptoms. The review also reported findings involving bone alkaline phosphatase and variable reproductive hormone measurements.[5]
Why the review was cautious
The review identified several limitations that affect how these findings should be interpreted.
- Study quality: The included studies had methodological and reporting deficiencies, with high risks of bias.
- Product standardization: The active ingredients and botanical sources used in the clinical studies were not consistently defined.
- Participant differences: Differences in menopausal status and study design made comparisons difficult.
- Outcome measurements: Some findings relied on self-reported symptoms, which can be influenced by recall and placebo effects.
- Safety information: The available studies did not provide sufficient evidence to establish long-term safety.
The authors concluded that the clinical evidence was inconclusive and called for better-designed studies with clearer botanical identification, standardized preparations, and more comprehensive safety monitoring.[5]
This distinction matters: a systematic review does not automatically confirm the effectiveness of a botanical. Its value also lies in identifying weaknesses in the research available at the time.
What the 2026 Critical Review Flags
A 2026 critical review by Zeng and colleagues examined the ethnobotany, phytochemistry, pharmacology, and safety considerations of Pueraria mirifica. It considered research published in multiple international and Chinese databases up to 2025.[6]
The review discussed several areas of research, including estrogen-related activity, bone-related findings, antioxidant activity, and other biological effects. It also summarized clinical findings involving menopausal vasomotor symptoms, urogenital symptoms, lipid metabolism, and bone mineral density.[6]
Standardization remains a challenge
One of the main issues identified by the review is the difficulty of translating research findings into consistent botanical preparations.
The authors highlighted two important gaps:
- Pharmacokinetic information: More research is needed to understand how the plant’s compounds are absorbed, distributed, metabolized, and eliminated.
- Quality control: Inconsistent standardization of botanical constituents makes it difficult to compare preparations and establish reliable research conditions.
The review also called for further mechanistic research and better evidence concerning long-term safety and standardized dose-response relationships.[6]
The 2026 review provides a broader assessment of the research landscape, but it does not remove the limitations identified in earlier clinical studies. Its conclusions should be read alongside the quality and design of the individual studies it discusses.
Laboratory and Animal Research
Research on Pueraria mirifica is not limited to human clinical studies. Laboratory experiments and animal models have also been used to investigate its biological activity.
The 2026 critical review describes preclinical research involving estrogen-related activity, bone-related effects, antioxidant activity, neuroprotective activity, and immunomodulatory activity. These findings provide areas for further investigation, but they do not establish corresponding health outcomes in people.[6]
Why preclinical findings matter
Laboratory research can help researchers investigate biological mechanisms under controlled conditions. Animal studies can provide additional information about biological responses in living systems.
However, results from cells or animals cannot automatically be applied to humans. Differences in biological systems, experimental conditions, botanical preparations, and exposure levels all affect how findings should be interpreted.
For a closer look at the plant’s compounds and their research context, see Pueraria Mirifica: Origin and Active Compounds.
What We Still Do Not Know
Although research has expanded, several important questions remain unanswered. The available evidence does not establish a complete picture of how different Pueraria mirifica preparations behave in humans or how their effects may vary between individuals.
- Long-term safety
- More comprehensive research is needed to understand safety with extended use.
- Botanical standardization
- Differences in plant sources, preparation methods, and constituent profiles make research comparisons difficult.
- Pharmacokinetics
- More information is needed about how the plant’s constituents behave inside the human body.
- Hormonal responses
- Clinical findings on reproductive hormone measurements have not established one consistent response across studies.
- Bone health
- Changes in bone-related biochemical markers do not independently establish long-term changes in bone density or fracture risk.
- Body composition
- The clinical studies discussed here do not establish predictable changes in body fat distribution or weight.
These gaps help explain why research findings should not be turned into broad promises about hormonal balance, body composition, or long-term health.
Anyone considering a botanical product should also consider the specific preparation, their health circumstances, and other products or medications they use. Our Routine and Safety Guide and Pueraria Mirifica Safety Guide provide additional information.
Research on Pueraria mirifica continues to develop. The most useful approach is to distinguish between findings from individual clinical studies, conclusions from systematic reviews, and early-stage laboratory or animal research.

Core Pueraria Care
Breast Capsules 60 capsules

Pure Pueraria
Pueraria Mirifica Herbal Extract in Liquid Type 25 ml. (High Concentration)
Key takeaways
- Human studies have mainly investigated menopausal symptoms, vaginal health, and bone-related measurements.
- The 2018 systematic review found promising research signals but concluded that clinical evidence remained inconclusive.
- The 2026 critical review highlighted gaps in pharmacokinetic research, botanical standardization, and long-term safety.
- Laboratory and animal findings provide research context but do not independently establish human health benefits.
- More standardized preparations and better-designed human studies are needed to clarify the evidence.
Frequently asked questions
What does research say about Pueraria mirifica?
Research includes human clinical studies, systematic reviews, laboratory experiments, and animal studies. Human studies have mainly examined menopausal symptoms, vaginal health, and bone-related measurements, but the overall evidence remains limited.
What did the 2018 systematic review conclude?
The review found that clinical evidence for menopausal symptom outcomes remained inconclusive because of methodological limitations, high risks of bias, and inconsistent botanical standardization.
What did the 2026 critical review identify?
The review highlighted gaps in pharmacokinetic research, quality control, long-term safety information, and standardized dose-response studies.
Has Pueraria mirifica been studied in humans?
Yes. Clinical studies have examined menopausal symptoms, vaginal health, reproductive hormone measurements, lipid profiles, and bone-related markers in women during and after menopause.
Do animal studies confirm the effects of Pueraria mirifica in humans?
No. Animal and laboratory studies can help investigate biological activity, but their findings cannot independently establish health outcomes in humans.
Is more research needed on Pueraria mirifica?
Yes. Research is still needed on botanical standardization, pharmacokinetics, long-term safety, and well-designed clinical outcomes.
Sources
- Lamlertkittikul S, Chandeying V. Efficacy and safety of Pueraria mirifica (Kwao Kruea Khao) for the treatment of vasomotor symptoms in perimenopausal women: Phase II Study. Journal of the Medical Association of Thailand. 2004;87(1):33-40. PubMed
- Virojchaiwong P, Suvithayasiri V, Itharat A. Comparison of Pueraria mirifica 25 and 50 mg for menopausal symptoms. Archives of Gynecology and Obstetrics. 2011;284(2):411-419. PubMed
- Manonai J, Chittacharoen A, Theppisai U, Theppisai H. Effect of Pueraria mirifica on vaginal health. Menopause. 2007;14(5):919-924. PubMed
- Manonai J, Chittacharoen A, Udomsubpayakul U, Theppisai H, Theppisai U. Effects and safety of Pueraria mirifica on lipid profiles and biochemical markers of bone turnover rates in healthy postmenopausal women. Menopause. 2008;15(3):530-535. PubMed
- Kongkaew C, Scholfield NC, Dhippayom T, Dilokthornsakul P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Pueraria candollei var. mirifica (Airy Shaw and Suvat.) Niyomdham for menopausal women: A systematic review of clinical trials and the way forward. Journal of Ethnopharmacology. 2018;216:162-174. PubMed
- Zeng H, Wen J, Chen M, Qiu Z, Huang S, Hao E, et al. Pueraria mirifica: a critical review of the ethnobotany, phytochemistry, pharmacology and challenges in standardization and safety. Frontiers in Pharmacology. 2026;17:1820644. PubMed
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Herbal supplements are not a substitute for medical advice. Talk to a healthcare professional before use if you are pregnant, breastfeeding, taking medication or being treated for a medical condition.
Published by
Pueraria Mirifica™


